EnWave Corporation
TSX VENTURE : ENW
FRANKFURT : E4U

EnWave Corporation

June 14, 2007 10:00 ET

EnWave Strengthens Its Management and Scientific Team

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 14, 2007) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or the "Company") has added four members to its management and scientific advisory team to provide guidance on corporate and legal affairs, corporate communications and financing, technology optimization, research and product development.

Paul MacNeill, of West Vancouver, will advise the Company's senior management on legal and corporate affairs. Mr. MacNeill is a Vancouver-based lawyer with extensive experience in advising emerging public companies on matters of securities and corporate law.

Paul Reinhart, of West Vancouver, joins the Company as its Executive Communications Advisor. He will support EnWave's President and Co-CEO, John McNicol, in the development and implementation of communications and financing strategies to meet the Company's business plan. Since retiring from a distinguished career in the National Hockey League in 1990, Mr. Reinhart has assisted a number of successful early-stage public companies.

Dr. Parastoo Yaghmaee, of Vancouver, joins the Company as a Scientific Advisor. Dr. Yaghmaee has a Ph.D. in Food Science from the University of British Columbia, and more than five years' experience working with EnWave's nutraREV and bioREV technology at the University, as well as seven years practical experience in food plant operations and product development. She will support the Co-CEO, Dr. Tim Durance, in the protection of the Company's intellectual property, in co-ordinating equipment trials with its strategic partners, and in developing its new laboratory facilities.

Mr. Steve Leptick, of Vancouver, joins the Company as a Product Development Advisor, to provide guidance in the areas of bioREV and nutraREV product development and technology start up protocols. Mr. Leptick is a chemical engineer with extensive experience assisting early-stage companies in qualifying new technology platforms for multinational customers in the personal care market.

Dr. Tim Durance, Chairman and Co-CEO of EnWave, stated: "We are delighted to have secured the assistance of these highly-successful advisors. Their knowledge and experience will be essential as we move ahead aggressively with the commercialization of our bioREV and nutraREV technologies in the biomedical and food sectors."

In connection with these appointments, the Company has granted incentive stock options to purchase a total of 450,000 common shares, exercisable at a price of $0.50 for five years.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating biological materials using Radiant Energy Vacuum technology, under its bioREV brand. bioREV technology combines microwave energy transfer with pressure control to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for medical applications that include dry vaccines, bone and tissue engineering, and drug delivery. More information about EnWave is available at www.enwave.net.

ON BEHALF OF THE BOARD

Dr. Tim Durance, Chairman & CO-CEO

Safe Harbour for Forward-Looking Information Statements: This release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's bioREV technology can or will be used to develop materials for the tissue engineering or drug delivery markets; even if the Company's bioREV technology can be used as described in this news release, there is no guarantee that such use will result in orders for the Company's bioREV technology.

The TSX Venture Exchange has neither approved nor disapproved the information contained herein.

Contact Information

  • EnWave Corporation
    Dr. Tim Durance
    Chairman and Co-CEO
    (604) 806-6110
    or
    EnWave Corporation
    John McNicol
    President and Co-CEO
    (604) 806-6110
    (604) 806-6112 (FAX)
    Website: www.enwave.net